{"gene":"ICAM3","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":1992,"finding":"ICAM-3 (ICAM-R/CDw50) was identified as a third ligand for LFA-1 (CD11a/CD18), consisting of five immunoglobulin superfamily domains, constitutively expressed on all leukocytes, binding LFA-1 through its two N-terminal domains.","method":"Expression cloning of cDNA, functional adhesion assays with LFA-1","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — two independent groups cloned and functionally characterized ICAM-3 in the same issue, with binding assays confirming LFA-1 interaction","pmids":["1448173","1448174"],"is_preprint":false},{"year":1993,"finding":"ICAM-3 and CDw50 are the same glycoprotein (~120 kDa), confirmed by immunochemical, functional, and peptide sequencing studies.","method":"Immunoprecipitation, peptide sequencing, functional assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (biochemical, functional, sequencing) confirming identity","pmids":["8325327"],"is_preprint":false},{"year":1993,"finding":"ICAM-3 is located at cellular uropods of T lymphoblasts and regulates the LFA-1/ICAM-1 adhesion pathway; engagement of ICAM-3 with activating mAb induces T cell aggregation dependent on LFA-1/ICAM-1 and enhances LFA-1 avidity for ICAM-1.","method":"Immunofluorescence microscopy, mAb blocking experiments, T lymphoblast adhesion assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — localization tied to functional consequence with multiple blocking experiments","pmids":["7901223"],"is_preprint":false},{"year":1993,"finding":"ICAM-3 acts as a co-stimulatory molecule for both resting and activated T lymphocytes; soluble purified ICAM-3 co-immobilized with anti-CD3 stimulated T lymphocyte activation (CD25 and CD69 expression), and this effect was blocked by anti-CD18, implicating LFA-1 as the mediating beta2 integrin.","method":"Immunoaffinity purification of ICAM-3, T cell co-stimulation assays, mAb blocking","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1/2 — purified protein reconstitution combined with mAb blocking, demonstrating mechanistic co-stimulation via LFA-1","pmids":["8223855"],"is_preprint":false},{"year":1994,"finding":"The LFA-1 binding site on ICAM-3 resides in immunoglobulin domain 1; purified ICAM-3 supports LFA-1-dependent adhesion in a temperature- and cation-dependent manner, and two ICAM-3 mAbs (CBR-IC3/1 and CBR-IC3/2) together are required to fully block LFA-1-dependent adhesion. ICAM-3 also provides a costimulatory proliferative signal to resting T lymphocytes.","method":"Adhesion assays with purified ICAM-3, mAb blocking, T cell proliferation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstituted adhesion with purified protein, multiple mAb characterizations, replicated findings on co-stimulation","pmids":["7905020"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 engagement induces tyrosine phosphorylation of proteins (125, 70, and 38 kDa), and this signaling is regulated by the CD45 tyrosine phosphatase; inhibitors of tyrosine kinase activity and certain anti-CD45 mAbs abolished ICAM-3-mediated cell aggregation.","method":"Western blot for phosphotyrosine, immunofluorescence, inhibitor studies, mAb blocking","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (biochemical and cell-based) linking ICAM-3 engagement to tyrosine kinase/phosphatase signaling","pmids":["7520448"],"is_preprint":false},{"year":1994,"finding":"The LFA-1 I domain contains the binding site for ICAM-3; two anti-LFA-1 mAbs (YTH81.5 and 122.2A5) with I domain epitopes selectively block adhesion to ICAM-3 but not ICAM-1, demonstrating that LFA-1 binds ICAM-1 and ICAM-3 in a selective manner using the I domain.","method":"T cell adhesion assays to immobilized ligands, mAb epitope mapping, COS cell transfection adhesion assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — clean adhesion assays with transfected cells and panel of blocking mAbs, epitope mapping to I domain","pmids":["7518468"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 engagement by activating mAb HP2/19 regulates T lymphocyte morphology, induces a heading uropod-like structure where ICAM-3 concentrates distally, and enhances integrin-mediated (LFA-1, VLA-4, VLA-5) T cell adhesion to endothelial cells and extracellular matrix ligands.","method":"Immunofluorescence microscopy, T cell adhesion assays to ICAM-1, VCAM-1, fibronectin fragments, mAb blocking","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — direct localization by microscopy linked to functional adhesion phenotypes with multiple blocking controls","pmids":["7525599"],"is_preprint":false},{"year":1994,"finding":"CDw50/ICAM-3 cross-linking on Jurkat T cells induces calcium mobilization dependent on extracellular Ca2+ uptake and tyrosine phosphorylation, and p56lck and p59fyn protein tyrosine kinases are physically associated with ICAM-3 (co-immunoprecipitation).","method":"Calcium flux assays, in vitro kinase assays, immunoprecipitation with specific antisera for p56lck and p59fyn","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1/2 — direct co-immunoprecipitation of kinases with ICAM-3 plus in vitro kinase activity assay","pmids":["7515097"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 surface expression on neutrophils is down-regulated by a proteolytic shedding mechanism upon activation (PMA or calcium ionophore), releasing soluble ICAM-3 into the medium; protease inhibitors abrogate this down-regulation. A soluble form of ICAM-3 is detectable in plasma of healthy humans.","method":"125I-anti-ICAM-3 internalization assay, immunoprecipitation of cell-free supernatants, radioimmunoassay of plasma, protease inhibitor treatment","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple biochemical methods (radiolabel, immunoprecipitation, RIA) demonstrating proteolytic shedding mechanism","pmids":["7525295"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 (CD50) signaling through CD50 increases beta1 and beta2 integrin avidity (not surface expression) to enhance T lymphocyte adhesion to TNF-stimulated endothelial cells and extracellular matrix proteins, demonstrated by combined blocking of both integrin families.","method":"T cell adhesion assays to endothelial cells and ECM, mAb blocking of integrin chains, flow cytometry for integrin surface expression","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean mechanistic dissection with reciprocal blocking experiments and functional consequence","pmids":["7515813"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 on neutrophils is phosphorylated predominantly on tyrosine residues, and protein tyrosine kinase activity (including hck and lyn src-family kinases) is associated with CD50 in immunoprecipitates from human neutrophils.","method":"Radiolabeling, immunoprecipitation, phosphoamino acid analysis, in vitro kinase assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay on immunoprecipitate with phosphoamino acid analysis","pmids":["7876557"],"is_preprint":false},{"year":1994,"finding":"The LFA-1 binding site on ICAM-3 involves a conserved integrin-binding motif in domain 1 including residues E37/T38, and Q75 (conserved in ICAM-1 and ICAM-2) confers specificity; electron microscopy shows ICAM-3 is a straight rod of 15 nm consistent with head-to-tail Ig domain arrangement.","method":"Electron microscopy, site-directed mutagenesis of ICAM-3, LFA-1-dependent adhesion assays","journal":"Cell adhesion and communication","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with structural EM and functional adhesion assays","pmids":["7531103"],"is_preprint":false},{"year":1995,"finding":"Alpha-d/CD18 (alphaDbeta2), a fourth beta2 integrin, binds ICAM-3 preferentially over ICAM-1, identifying ICAM-3 as a preferred ligand for this integrin.","method":"Transfection of alpha-d cDNA, adhesion assays comparing ICAM-1 vs. ICAM-3","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — functional adhesion assays with transfected cells definitively characterizing ligand selectivity","pmids":["8777714"],"is_preprint":false},{"year":1995,"finding":"ICAM-3 interacts with Mac-1 (CD11b) or p150,95 (CD11c) neither from lymphoid cells nor from neutrophils; purified Mac-1 does not support adhesion of ICAM-3-expressing transfectants, establishing ICAM-3 as not a counter-receptor for Mac-1 or p150,95.","method":"CHO cell transfection adhesion assays with purified Mac-1, L cell transfectants","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted adhesion assays with purified proteins and transfectants","pmids":["7737271"],"is_preprint":false},{"year":1996,"finding":"The LFA-1 binding site on ICAM-3 maps exclusively to domain 1; deletion of individual Ig domains and chimeras with CD21 showed domain 1 is necessary and sufficient, and point mutagenesis identified five contact residues (Asn23, Ser25, Glu37, Phe54, Gln75) predicted to cluster on the BED face and C/E/FG regions of domain 1.","method":"Domain deletion mutagenesis, ICAM-3/CD21 chimeras, point mutagenesis (45 mutants), LFA-1 adhesion assays, mAb epitope mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — extensive mutagenesis (45 point mutants) combined with domain chimeras and functional adhesion assays","pmids":["8798624"],"is_preprint":false},{"year":1997,"finding":"The LFA-1 I domain acts as a transient, Mg2+-dependent binding module for ICAM-3 in hydrodynamic flow; GPI-anchored I domain cells roll on ICAM-3 bilayers, and the LFA-1-activating antibody MEM-83 (which stimulates ICAM-1 binding) blocks interaction with ICAM-3, demonstrating distinct modes of I domain interaction with ICAM-1 vs. ICAM-3.","method":"GPI-anchored I domain cell expression, flow chamber rolling assays on lipid bilayers with purified ICAM-1/ICAM-3","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstituted system with purified ligands and defined adhesion assay under controlled flow","pmids":["9271587"],"is_preprint":false},{"year":1998,"finding":"The LFA-1 binding site on ICAM-3 domain 1 includes residues on both the ABED face and the GFC face, unlike ICAM-1 where only GFC face residues interact with LFA-1; mutagenesis of 18 positions identified 7 residues reducing or abolishing LFA-1 adhesion.","method":"Point mutagenesis of 18 residues in domain 1, LFA-1 adhesion assays, mAb blocking studies","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with functional adhesion assays","pmids":["9686599"],"is_preprint":false},{"year":1998,"finding":"Engagement of ICAM-3 by a mAb recognizing the alphaLbeta2-binding region activates PMN homotypic aggregation through outside-in signaling: activating tyrosine kinase and PKC, reorganizing the cytoskeleton, and activating constitutive surface beta2 integrins without inducing degranulation or beta2 integrin recruitment.","method":"mAb engagement (Fab and F(ab')2 fragments), aggregation assays, kinase activity measurements, cytoskeletal reorganization assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — Fab fragment experiments exclude Fc-mediated effects; multiple kinase assays and functional readouts","pmids":["9834117"],"is_preprint":false},{"year":1998,"finding":"Co-engagement of ICAM-3 (domain 1 epitopes) with Fc receptors (FcgammaRI or FcgammaRII) on monocytes is required for maximal chemokine secretion (MIP-1alpha, IL-8, MCP-1); ICAM-3 engagement also induces monocyte spreading via direct outside-in signaling (Fab/F(ab')2-dependent).","method":"Immobilized mAb engagement, Fab/F(ab')2 fragments, chemokine ELISA, microscopy for cell spreading","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — Fab fragment controls confirm direct ICAM-3 outside-in signaling; multiple cytokine readouts","pmids":["9605163"],"is_preprint":false},{"year":1999,"finding":"ICAM-3 on apoptotic leukocytes acts as a phagocytic recognition signal for macrophages; the first Ig-like domain of ICAM-3 mediates macrophage recognition, and its binding preference shifts from LFA-1 to macrophage CD14 during apoptosis, enabling phagocytosis.","method":"mAb blockade of macrophage-apoptotic cell interactions, ICAM-3 transfection into non-leukocytes, apoptosis triggered by multiple stimuli","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — mAb blocking, transfection into non-leukocytes, and multiple apoptotic stimuli provide strong evidence for mechanism","pmids":["10352301"],"is_preprint":false},{"year":2000,"finding":"DC-SIGN, a DC-specific C-type lectin, binds ICAM-3 expressed on resting T cells with high affinity to mediate transient DC-T cell adhesion; anti-DC-SIGN antibodies inhibit DC-induced proliferation of resting T cells, indicating DC-SIGN/ICAM-3 stabilizes the DC-T cell contact zone.","method":"Binding assays, mAb inhibition of DC-T cell interaction and T cell proliferation, expression analysis of DC-SIGN on DC in vitro and in vivo","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — identification of novel receptor with functional blocking experiments, replicated in multiple systems","pmids":["10721994"],"is_preprint":false},{"year":2000,"finding":"LFA-1 (alphaLbeta2) preferentially binds ICAM-3 as its primary ligand supporting neutrophil homotypic adhesion at higher shear rates (>300 s-1), whereas Mac-1 is the predominant integrin at lower shear rates (~100 s-1); the contributions of LFA-1 and Mac-1 to ICAM-3-dependent aggregation are regulated by shear magnitude and stimulus duration.","method":"Cone-plate viscometer shear experiments, mAb blocking with panel of anti-LFA-1, anti-Mac-1, and anti-ICAM-3 antibodies, flow cytometry for aggregate formation kinetics","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — quantitative adhesion efficiency model with systematic mAb blocking across shear range","pmids":["10725740"],"is_preprint":false},{"year":2001,"finding":"ICAM-3 N-linked oligosaccharides are mainly of tri- and tetra-antennary complex-type (~60% containing poly N-acetyllactosamine chains with type 1 structure), with a small amount of high-mannose type; approximately 6 mol oligosaccharides per mol ICAM-3.","method":"Hydrazinolysis to release N-glycans, paper electrophoresis, lectin column chromatography, sequential exo/endo-glycosidase digestion, methylation analysis","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic structural analysis using multiple biochemical methods","pmids":["11179968"],"is_preprint":false},{"year":2002,"finding":"ICAM-3 is specifically clustered at the region of the T lymphocyte surface that initiates contact with APCs (pre-immunological synapse), as shown by time-lapse imaging; ICAM-3 promotes early intracellular signaling and cytoskeletal rearrangement before antigen recognition.","method":"Time-lapse live-cell imaging, mAb blocking, analysis of T cell-APC conjugate formation, signaling and cytoskeletal assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — live-cell time-lapse imaging directly linking ICAM-3 clustering to functional consequence (early signaling and cytoskeletal rearrangement)","pmids":["11812993"],"is_preprint":false},{"year":2006,"finding":"DC-SIGN binds ICAM-3 from granulocytes via Lewis x glycan residues on ICAM-3; fucosyltransferase IX (FUT IX) is the main enzyme mediating Lewis x synthesis on ICAM-3, with FUT IV contributing to a lesser extent. ICAM-3 from granulocytes but not other leukocytes binds DC-SIGN.","method":"Recombinant DC-SIGN binding assays, anti-Lewis x mAbs, MALDI-TOF mass spectrometry, cotransfection studies with multiple FUTs, DC-SIGN-expressing immature DC binding experiments","journal":"Glycobiology","confidence":"High","confidence_rationale":"Tier 1 — mass spectrometry structural confirmation plus functional FUT cotransfection assays with multiple enzymes","pmids":["17145745"],"is_preprint":false},{"year":2010,"finding":"ICAM-3 stimulates cancer cell migration and invasion via an ICAM-3/Akt/CREB/MMP pathway; ICAM-3 overexpression increases Akt phosphorylation, activates CREB, and upregulates MMP-2 and MMP-9 expression and activity, leading to enhanced migration/invasion independent of p53 and PTEN status.","method":"Stable ICAM-3-overexpressing transfectants, migration/invasion assays, Akt inhibitor treatment, siRNA knockdown of CREB, gelatin zymography for MMP activity","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays with OE and inhibitor/knockdown, but single-lab study","pmids":["19956847"],"is_preprint":false},{"year":2011,"finding":"Apoptotic cell-derived ICAM-3 promotes macrophage chemoattraction via ICAM-3-bearing microparticles released during apoptosis; ICAM-3 on apoptotic cells mediates domain 1-2-dependent tethering to macrophages. ICAM-3-deficient microparticles show profound defect in chemotaxis.","method":"Novel anti-ICAM-3 mAbs (blocking and non-blocking), ICAM-3-deficient apoptotic leukocytes, microparticle isolation, chemotaxis assays, phagocytosis assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches including blocking mAbs and ICAM-3-deficient cells, two distinct functional readouts (chemotaxis and tethering)","pmids":["22117198"],"is_preprint":false},{"year":2012,"finding":"The RUNX3 transcription factor negatively regulates ICAM-3 gene expression; ICAM-3 promoter activity depends on RUNX binding sites, and siRNA-mediated reduction of RUNX3 increases ICAM-3 mRNA; ICAM-3 levels decrease during monocyte-to-macrophage differentiation correlating with increased RUNX3.","method":"Promoter-reporter assays, chromatin immunoprecipitation (RUNX binding in vivo), siRNA knockdown of RUNX3, protein level analysis during macrophage differentiation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — promoter mutagenesis, ChIP, and gene silencing providing convergent evidence for RUNX3 as a negative transcriptional regulator","pmids":["22479382"],"is_preprint":false},{"year":2013,"finding":"ICAM-3 and LFA-1 act as recognition receptors in phagocytosis portals of macrophages for engulfment of apoptotic neutrophils; ICAM-3 on macrophages is upregulated upon exposure to apoptotic neutrophils, blocking ICAM-3 on macrophages or apoptotic neutrophils reduces phagocytosis, and ICAM-3/LFA-1 co-localize in phagocytic portals.","method":"Gene silencing (siRNA), blocking antibodies, fluorescence microscopy, phagocytosis quantification","journal":"Apoptosis","confidence":"High","confidence_rationale":"Tier 2 — reciprocal siRNA and blocking experiments on both cell types with co-localization evidence in phagocytic portals","pmids":["23775590"],"is_preprint":false},{"year":2018,"finding":"ICAM-3 recruits and binds Src kinase through the YLPL motif in its intracellular domain, activating PI3K-AKT phosphorylation cascades that enhance SOX2 and OCT4 activity to maintain cancer cell stemness; p-AKT also facilitates p50 nuclear translocation which feeds back to enhance ICAM-3 expression by binding its promoter.","method":"siRNA screen, co-immunoprecipitation of ICAM-3 with Src, PI3K/Src inhibitor treatment, in vivo tumor and metastasis models with shICAM-3 cells","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus pharmacological inhibition plus in vivo models, but single-lab study","pmids":["29477378"],"is_preprint":false},{"year":2018,"finding":"ICAM-3 mediates tumor metastasis via a LFA-1-ICAM-3-ERM-dependent mechanism; ICAM-3 binds LFA-1 through its extracellular domain and ERM scaffold proteins and lamellipodia through its intracellular domain, creating tension that facilitates cell motility; extracellular or intracellular mutants of ICAM-3 abolish metastasis, and LFA-1 antibody or Lifitegrast inhibit ICAM-3-LFA-1-mediated metastasis.","method":"ICAM-3 extracellular/intracellular domain mutants, co-immunoprecipitation with ERM proteins, in vitro and in vivo metastasis assays, LFA-1 antibody treatment","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 — domain mutants plus co-IP plus in vivo models, single lab","pmids":["29729315"],"is_preprint":false},{"year":1992,"finding":"ICAM-3 (CDw50) is constitutively non-phosphorylated at baseline but becomes rapidly phosphorylated on serine residues within 1–5 minutes upon stimulation with protein kinase C activators (PMA, PDB, mezerein), and PKC inhibitors (staurosporine, H-7) reduce this phosphorylation, implicating PKC-mediated mechanisms in ICAM-3 phosphorylation.","method":"Radiolabeling (32P), immunoprecipitation, phosphoamino acid analysis, PKC inhibitor treatment","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — biochemical phosphorylation analysis with phosphoamino acid identification and pharmacological inhibition","pmids":["1730238"],"is_preprint":false},{"year":2004,"finding":"Activation of ICAM-3 on human bone marrow endothelial cells by crosslinking with specific antibodies causes loss of endothelial cell-cell contacts and drop in electrical resistance; biochemical analysis reveals ICAM-3 associates with moesin (and later ezrin) upon crosslinking, and induces production of reactive oxygen species (ROS) that mediate endothelial permeability.","method":"ICAM-3 crosslinking, electrical resistance measurement of endothelial monolayers, immunocytochemistry, co-immunoprecipitation of moesin/ezrin with ICAM-3, ROS measurement","journal":"Journal of vascular research","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus functional monolayer integrity assay with ROS detection, but single lab","pmids":["14726630"],"is_preprint":false},{"year":2011,"finding":"Kidins220/ARMS protein co-immunoprecipitates with ICAM-3 and co-localizes at the uropod of polarized T lymphocytes; disruption of cell polarity (PKC-dependent) impairs Kidins220/ARMS association with ICAM-3; Kidins220/ARMS knockdown promotes T cell migration, identifying it as a uropod regulator linked to ICAM-3.","method":"Co-immunoprecipitation, immunofluorescence microscopy in polarized T cells, siRNA knockdown, directed migration assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 — single co-IP with partial mechanistic follow-up (PKC dependence and migration assays)","pmids":["21381019"],"is_preprint":false}],"current_model":"ICAM-3 (CD50) is an immunoglobulin superfamily cell adhesion molecule constitutively expressed on all leukocytes that functions as the primary LFA-1 (CD11a/CD18) ligand on resting T cells—binding through residues on both faces of its first Ig domain—and also serves as a ligand for alphaDbeta2 and DC-SIGN; it concentrates at the T cell uropod and the initial DC-contact zone to promote antigen-independent adhesion and provide LFA-1-mediated co-stimulation through outside-in signaling (activating p56lck, p59fyn, tyrosine phosphorylation, and Ca2+ flux, regulated by CD45 phosphatase), is shed proteolytically from activated neutrophils as a soluble form, acts as an altered-recognition eat-me signal on apoptotic leukocytes engaging macrophage CD14, and drives cancer cell migration/stemness through intracellular YLPL-Src-PI3K-AKT and ERM-lamellipodia interactions."},"narrative":{"teleology":[{"year":1992,"claim":"Identification of ICAM-3 as a third LFA-1 ligand on leukocytes established a new adhesion molecule in the immunoglobulin superfamily with distinct expression and potential function from ICAM-1 and ICAM-2.","evidence":"Two independent groups expression-cloned ICAM-3 cDNA and demonstrated LFA-1-dependent adhesion in functional assays","pmids":["1448173","1448174"],"confidence":"High","gaps":["Binding-site residues on ICAM-3 not yet mapped","Signaling consequences of engagement unknown","Relationship to CDw50 antigen not formally proven"]},{"year":1992,"claim":"Demonstration that ICAM-3 cytoplasmic domain undergoes rapid PKC-dependent serine phosphorylation revealed that ICAM-3 is a regulated signaling-competent molecule, not merely a passive adhesion scaffold.","evidence":"32P-radiolabeling and phosphoamino acid analysis of immunoprecipitated ICAM-3 with PKC activators and inhibitors","pmids":["1730238"],"confidence":"High","gaps":["Specific serine residues not identified","Functional consequence of phosphorylation not determined"]},{"year":1993,"claim":"Localization of ICAM-3 to the T cell uropod and demonstration that its engagement enhances LFA-1 avidity for ICAM-1 established ICAM-3 as an active regulator of integrin-mediated adhesion rather than simply a redundant LFA-1 counter-receptor.","evidence":"Immunofluorescence microscopy of T lymphoblasts combined with mAb blocking experiments and adhesion assays","pmids":["7901223","8223855"],"confidence":"High","gaps":["Mechanism linking ICAM-3 engagement to integrin activation not defined","Whether co-stimulatory function requires uropod localization unknown"]},{"year":1994,"claim":"A wave of signaling studies revealed that ICAM-3 engagement triggers tyrosine phosphorylation, calcium flux, and association with Src-family kinases (p56lck, p59fyn in T cells; hck, lyn in neutrophils), with CD45 phosphatase serving as a negative regulator — defining ICAM-3 as a bona fide outside-in signaling receptor.","evidence":"Co-immunoprecipitation of kinases with ICAM-3, in vitro kinase assays, phosphotyrosine blotting, calcium flux measurements, and CD45 mAb/inhibitor blocking in T cells and neutrophils","pmids":["7520448","7515097","7876557"],"confidence":"High","gaps":["Direct phosphorylation substrates downstream of Src kinases not identified","Whether kinase association is direct or scaffolded unknown"]},{"year":1994,"claim":"Mapping the LFA-1 binding site to Ig domain 1 of ICAM-3 and defining key contact residues (E37, T38, Q75) by mutagenesis and electron microscopy provided the first structural framework for ICAM-3–LFA-1 interaction.","evidence":"Site-directed mutagenesis of domain 1, LFA-1 adhesion assays, domain deletion/chimera analysis, electron microscopy showing 15 nm rod","pmids":["7531103","7905020","8798624"],"confidence":"High","gaps":["No crystal structure of ICAM-3 domain 1 or ICAM-3–I domain complex","Role of glycosylation in LFA-1 binding not addressed"]},{"year":1994,"claim":"Discovery of proteolytic shedding of ICAM-3 from activated neutrophils and detection of soluble ICAM-3 in plasma identified a regulatory mechanism for surface ICAM-3 levels with potential immunomodulatory function.","evidence":"125I-radiolabel internalization assay, immunoprecipitation of supernatants, radioimmunoassay of plasma, protease inhibitor treatment","pmids":["7525295"],"confidence":"High","gaps":["Identity of the protease(s) responsible for shedding not determined","Functional role of soluble ICAM-3 in vivo unclear"]},{"year":1995,"claim":"Identification of αDβ2 as a second integrin receptor preferring ICAM-3 over ICAM-1 expanded the functional repertoire of ICAM-3 beyond LFA-1, while Mac-1 and p150,95 were excluded as ICAM-3 receptors.","evidence":"Transfection of αD cDNA with adhesion assays comparing ICAM-1 vs ICAM-3; purified Mac-1 adhesion assays with ICAM-3 transfectants","pmids":["8777714","7737271"],"confidence":"High","gaps":["Physiological context for αDβ2–ICAM-3 interaction not defined","Whether αDβ2 and LFA-1 compete for the same ICAM-3 binding site unknown"]},{"year":1998,"claim":"Refined mutagenesis revealed that LFA-1 contacts both the ABED and GFC faces of ICAM-3 domain 1, unlike ICAM-1 where only the GFC face is used, establishing a structurally distinct binding mode that explains selective antibody blocking patterns.","evidence":"Systematic point mutagenesis of 18 residues in domain 1 combined with LFA-1 adhesion assays and mAb mapping","pmids":["9686599"],"confidence":"High","gaps":["No co-crystal structure to confirm dual-face binding model","Conformational dynamics of the interaction not addressed"]},{"year":1999,"claim":"The discovery that ICAM-3 on apoptotic leukocytes shifts from an LFA-1 ligand to a macrophage CD14 ligand established ICAM-3 as a phagocytic recognition ('eat-me') signal, revealing a non-adhesion function for this molecule.","evidence":"mAb blockade of macrophage–apoptotic cell interactions, ICAM-3 transfection into non-leukocyte cells, multiple apoptotic stimuli","pmids":["10352301"],"confidence":"High","gaps":["Nature of the molecular change on ICAM-3 during apoptosis not defined","Whether glycan modification mediates the ligand switch unknown"]},{"year":2000,"claim":"Identification of DC-SIGN as a high-affinity ICAM-3 receptor on dendritic cells established a new axis for antigen-independent DC–T cell contact that initiates the immunological synapse.","evidence":"Binding assays and mAb inhibition of DC-SIGN–ICAM-3 interaction blocking DC-induced T cell proliferation","pmids":["10721994"],"confidence":"High","gaps":["Relative contributions of DC-SIGN vs LFA-1 to DC–T cell adhesion not quantified","Downstream signaling in DC upon DC-SIGN–ICAM-3 engagement not characterized"]},{"year":2002,"claim":"Live-cell imaging demonstrated that ICAM-3 clusters at the initial T cell–APC contact zone before antigen recognition, positioning it as a key molecule in pre-immunological synapse formation and early signaling.","evidence":"Time-lapse live-cell imaging of T cell–APC conjugate formation with mAb blocking and cytoskeletal analysis","pmids":["11812993"],"confidence":"High","gaps":["Molecular mechanism driving ICAM-3 clustering to the contact zone not identified","Whether ICAM-3 clustering requires DC-SIGN engagement or LFA-1 engagement unclear"]},{"year":2006,"claim":"Demonstration that DC-SIGN recognizes Lewis x glycan structures on ICAM-3 (synthesized by FUT IX) resolved the glycan basis of the DC-SIGN–ICAM-3 interaction and explained cell-type-specific binding (granulocyte ICAM-3 binds DC-SIGN, other leukocyte ICAM-3 does not).","evidence":"MALDI-TOF mass spectrometry of ICAM-3 glycans, FUT cotransfection experiments, anti-Lewis x mAb blocking, DC-SIGN binding assays","pmids":["17145745"],"confidence":"High","gaps":["Whether Lewis x on T cell ICAM-3 is regulated during activation unknown","Structural basis of DC-SIGN selectivity for Lewis x on ICAM-3 vs other glycoproteins not resolved"]},{"year":2011,"claim":"Demonstration that apoptotic cells release ICAM-3-bearing microparticles that serve as macrophage chemoattractants extended the eat-me signal concept to a 'find-me' signal, showing ICAM-3 domains 1–2 mediate both tethering and chemotaxis.","evidence":"ICAM-3-deficient apoptotic leukocytes, microparticle isolation, chemotaxis and phagocytosis assays with blocking and non-blocking mAbs","pmids":["22117198"],"confidence":"High","gaps":["Receptor on macrophages mediating ICAM-3-microparticle chemotaxis not definitively identified","Whether soluble shed ICAM-3 and microparticle-bound ICAM-3 have overlapping or distinct functions unclear"]},{"year":2018,"claim":"In cancer cells, ICAM-3 was shown to recruit Src kinase via the intracellular YLPL motif and activate PI3K–AKT signaling to maintain stemness (SOX2/OCT4) and drive metastasis through ERM-scaffold-dependent lamellipodia formation, extending ICAM-3 function beyond immune adhesion.","evidence":"Co-immunoprecipitation of ICAM-3 with Src and ERM proteins, PI3K/Src inhibitor treatment, intracellular/extracellular domain mutants, in vivo tumor and metastasis models","pmids":["29477378","29729315"],"confidence":"Medium","gaps":["Cancer-related findings from single laboratories, not independently confirmed","Whether YLPL-Src and ERM interactions occur simultaneously or are context-dependent unknown","Relevance of these mechanisms to normal leukocyte biology not tested"]},{"year":null,"claim":"No atomic-resolution structure of ICAM-3 (alone or in complex with LFA-1, DC-SIGN, or CD14) exists, and the molecular basis of the apoptotic ligand switch from LFA-1 to CD14 remains undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of ICAM-3 or its complexes","Mechanism of ICAM-3 modification during apoptosis unknown","Identity of the sheddase(s) cleaving ICAM-3 from neutrophils not determined","In vivo phenotype of ICAM-3 deficiency in humans or knockout animals not reported"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,3,4,7,10,21,22]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[5,8,18,19]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[13,20,21]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,7,9,24]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[9,27]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[27]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,5,8,21,24,29]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[2,7,10,22,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,8,18,26,30]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[20,27,29]}],"complexes":[],"partners":["ITGAL","ITGB2","CD209","CD14","LCK","FYN","MSN","EZR"],"other_free_text":[]},"mechanistic_narrative":"ICAM-3 (CD50) is an immunoglobulin superfamily adhesion molecule constitutively expressed on leukocytes that functions as a principal ligand for LFA-1 (αLβ2) and αDβ2 integrins, and for the C-type lectin DC-SIGN, thereby orchestrating leukocyte adhesion, T cell co-stimulation, dendritic cell–T cell contact, and apoptotic cell clearance. LFA-1 binds ICAM-3 through its I domain at residues distributed across both the ABED and GFC faces of Ig domain 1, a binding mode distinct from that used for ICAM-1; this interaction mediates outside-in signaling that activates Src-family kinases (p56lck, p59fyn, hck, lyn), PKC, and tyrosine phosphorylation cascades regulated by the CD45 phosphatase, resulting in calcium mobilization, cytoskeletal reorganization, integrin avidity upregulation, and T cell co-stimulation [PMID:1448173, PMID:7905020, PMID:7515097, PMID:7520448, PMID:9686599]. ICAM-3 concentrates at the T cell uropod and the initial T cell–APC contact zone to promote early antigen-independent adhesion and signaling prior to immunological synapse formation, and DC-SIGN on dendritic cells engages Lewis x glycans on ICAM-3 to stabilize this contact [PMID:7525599, PMID:11812993, PMID:10721994, PMID:17145745]. On apoptotic leukocytes, ICAM-3 undergoes an altered-recognition switch from LFA-1 to macrophage CD14, functioning as an eat-me signal that promotes phagocytosis and releases ICAM-3-bearing microparticles that attract macrophages; additionally, in cancer cells, intracellular ICAM-3 recruits Src via its YLPL motif and signals through PI3K–AKT to drive migration, invasion, and stemness maintenance [PMID:10352301, PMID:22117198, PMID:29477378, PMID:29729315]."},"prefetch_data":{"uniprot":{"accession":"P32942","full_name":"Intercellular adhesion molecule 3","aliases":["CDw50","ICAM-R"],"length_aa":547,"mass_kda":59.5,"function":"Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring apoptotic neutrophil phagocytosis by macrophages (PubMed:1448173, PubMed:1448174, PubMed:23775590, PubMed:8325327, PubMed:8459213). Is also a ligand for integrin ITGAD/ITGB2 (PubMed:8777714). Ligand of CD209 on dendritic cells (DC) through an integrin-independent mechanism that requires Ca(2+) and that forms a first contact between DC and resting T cell, facilitating the downstream DC-T cell clustering process and DC-induced proliferation of resting T Cells (PubMed:10721994)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P32942/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ICAM3","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ICAM3","total_profiled":1310},"omim":[{"mim_id":"614371","title":"DENGUE VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/614371"},{"mim_id":"614088","title":"INTRACELLULAR ADHESION MOLECULE 4; ICAM4","url":"https://www.omim.org/entry/614088"},{"mim_id":"605872","title":"C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER M; CLEC4M","url":"https://www.omim.org/entry/605872"},{"mim_id":"604672","title":"CD209 ANTIGEN; CD209","url":"https://www.omim.org/entry/604672"},{"mim_id":"602037","title":"RAS HOMOLOG GENE FAMILY, MEMBER H; RHOH","url":"https://www.omim.org/entry/602037"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":167.4},{"tissue":"lymphoid tissue","ntpm":88.8}],"url":"https://www.proteinatlas.org/search/ICAM3"},"hgnc":{"alias_symbol":["CDW50","ICAM-R","CD50"],"prev_symbol":[]},"alphafold":{"accession":"P32942","domains":[{"cath_id":"2.60.40.10","chopping":"33-113","consensus_level":"high","plddt":92.563,"start":33,"end":113},{"cath_id":"2.60.40.10","chopping":"118-215","consensus_level":"high","plddt":95.4077,"start":118,"end":215},{"cath_id":"2.60.40.10","chopping":"223-311","consensus_level":"high","plddt":95.2322,"start":223,"end":311},{"cath_id":"2.60.40.10","chopping":"317-397","consensus_level":"high","plddt":94.5023,"start":317,"end":397},{"cath_id":"2.60.40.10","chopping":"404-479","consensus_level":"high","plddt":91.5886,"start":404,"end":479}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P32942","model_url":"https://alphafold.ebi.ac.uk/files/AF-P32942-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P32942-F1-predicted_aligned_error_v6.png","plddt_mean":87.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ICAM3","jax_strain_url":"https://www.jax.org/strain/search?query=ICAM3"},"sequence":{"accession":"P32942","fasta_url":"https://rest.uniprot.org/uniprotkb/P32942.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P32942/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P32942"}},"corpus_meta":[{"pmid":"10721994","id":"PMC_10721994","title":"Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10721994","citation_count":1336,"is_preprint":false},{"pmid":"12783086","id":"PMC_12783086","title":"Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses.","date":"2003","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/12783086","citation_count":383,"is_preprint":false},{"pmid":"1448173","id":"PMC_1448173","title":"Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1448173","citation_count":322,"is_preprint":false},{"pmid":"8777714","id":"PMC_8777714","title":"A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3.","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8777714","citation_count":224,"is_preprint":false},{"pmid":"1448174","id":"PMC_1448174","title":"Cloning and characterization of a new intercellular adhesion molecule ICAM-R.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1448174","citation_count":198,"is_preprint":false},{"pmid":"7905020","id":"PMC_7905020","title":"Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7905020","citation_count":155,"is_preprint":false},{"pmid":"7901223","id":"PMC_7901223","title":"ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7901223","citation_count":150,"is_preprint":false},{"pmid":"8129777","id":"PMC_8129777","title":"Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis.","date":"1994","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/8129777","citation_count":133,"is_preprint":false},{"pmid":"10352301","id":"PMC_10352301","title":"Macrophage recognition of ICAM-3 on apoptotic leukocytes.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10352301","citation_count":125,"is_preprint":false},{"pmid":"11812993","id":"PMC_11812993","title":"Role of ICAM-3 in the initial interaction of T lymphocytes and APCs.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11812993","citation_count":122,"is_preprint":false},{"pmid":"8568591","id":"PMC_8568591","title":"The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium.","date":"1995","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8568591","citation_count":119,"is_preprint":false},{"pmid":"12021323","id":"PMC_12021323","title":"Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission.","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12021323","citation_count":103,"is_preprint":false},{"pmid":"7520448","id":"PMC_7520448","title":"Induction of tyrosine phosphorylation during ICAM-3 and LFA-1-mediated intercellular adhesion, and its regulation by the CD45 tyrosine phosphatase.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7520448","citation_count":98,"is_preprint":false},{"pmid":"21098395","id":"PMC_21098395","title":"Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFN{gamma}: role of CD18, ICAM-1, and ICAM-3.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21098395","citation_count":89,"is_preprint":false},{"pmid":"22117198","id":"PMC_22117198","title":"Apoptotic cell-derived ICAM-3 promotes both macrophage chemoattraction to and tethering of apoptotic cells.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22117198","citation_count":88,"is_preprint":false},{"pmid":"8223855","id":"PMC_8223855","title":"ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8223855","citation_count":88,"is_preprint":false},{"pmid":"19230080","id":"PMC_19230080","title":"Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN).","date":"2009","source":"The British journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/19230080","citation_count":86,"is_preprint":false},{"pmid":"17001080","id":"PMC_17001080","title":"The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin).","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17001080","citation_count":85,"is_preprint":false},{"pmid":"7518468","id":"PMC_7518468","title":"Involvement of the \"I\" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7518468","citation_count":82,"is_preprint":false},{"pmid":"15111305","id":"PMC_15111305","title":"Dynamic populations of dendritic cell-specific ICAM-3 grabbing nonintegrin-positive immature dendritic cells and liver/lymph node-specific ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the paracortex of human lymph nodes.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15111305","citation_count":78,"is_preprint":false},{"pmid":"19956847","id":"PMC_19956847","title":"ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19956847","citation_count":75,"is_preprint":false},{"pmid":"10931137","id":"PMC_10931137","title":"Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease.","date":"2000","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10931137","citation_count":75,"is_preprint":false},{"pmid":"7525599","id":"PMC_7525599","title":"ICAM-3 regulates lymphocyte morphology and integrin-mediated T cell interaction with endothelial cell and extracellular matrix ligands.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7525599","citation_count":73,"is_preprint":false},{"pmid":"20080962","id":"PMC_20080962","title":"Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20080962","citation_count":72,"is_preprint":false},{"pmid":"7515097","id":"PMC_7515097","title":"CD50 (intercellular adhesion molecule 3) stimulation induces calcium mobilization and tyrosine phosphorylation through p59fyn and p56lck in Jurkat T cell line.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7515097","citation_count":65,"is_preprint":false},{"pmid":"16134084","id":"PMC_16134084","title":"Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16134084","citation_count":61,"is_preprint":false},{"pmid":"9271587","id":"PMC_9271587","title":"The lymphocyte function-associated antigen 1 I domain is a transient binding module for intercellular adhesion molecule (ICAM)-1 and ICAM-3 in hydrodynamic flow.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9271587","citation_count":57,"is_preprint":false},{"pmid":"9174593","id":"PMC_9174593","title":"RANTES stimulation of T lymphocyte adhesion and activation: role for LFA-1 and ICAM-3.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9174593","citation_count":54,"is_preprint":false},{"pmid":"7515813","id":"PMC_7515813","title":"Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in beta 1 and beta 2 integrin function.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7515813","citation_count":54,"is_preprint":false},{"pmid":"7542573","id":"PMC_7542573","title":"Adhesion molecules intercellular adhesion molecule-1 (ICAM-1), ICAM-3 and B7 are not expressed by epithelium in normal or inflamed colon.","date":"1995","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7542573","citation_count":53,"is_preprint":false},{"pmid":"14970226","id":"PMC_14970226","title":"DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14970226","citation_count":50,"is_preprint":false},{"pmid":"22205703","id":"PMC_22205703","title":"Retagging identifies dendritic cell-specific intercellular adhesion molecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN) protein as a novel receptor for a major allergen from house dust mite.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22205703","citation_count":50,"is_preprint":false},{"pmid":"7516162","id":"PMC_7516162","title":"Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium. Comparison with other adhesion molecules.","date":"1994","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/7516162","citation_count":45,"is_preprint":false},{"pmid":"7836774","id":"PMC_7836774","title":"Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7836774","citation_count":44,"is_preprint":false},{"pmid":"7916296","id":"PMC_7916296","title":"Intercellular adhesion molecules (ICAM)-1 ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7916296","citation_count":44,"is_preprint":false},{"pmid":"10427988","id":"PMC_10427988","title":"Co-stimulation of T cells results in distinct IL-10 and TNF-alpha cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10427988","citation_count":43,"is_preprint":false},{"pmid":"10374960","id":"PMC_10374960","title":"Human T-cell leukaemia/lymphoma virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7.","date":"1999","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/10374960","citation_count":43,"is_preprint":false},{"pmid":"10725740","id":"PMC_10725740","title":"Shear and time-dependent changes in Mac-1, LFA-1, and ICAM-3 binding regulate neutrophil homotypic adhesion.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10725740","citation_count":42,"is_preprint":false},{"pmid":"8798624","id":"PMC_8798624","title":"Localization of the binding site on intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen 1 (LFA-1).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798624","citation_count":41,"is_preprint":false},{"pmid":"7525295","id":"PMC_7525295","title":"Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7525295","citation_count":40,"is_preprint":false},{"pmid":"8325327","id":"PMC_8325327","title":"CDw50 and ICAM-3: two names for the same molecule.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8325327","citation_count":40,"is_preprint":false},{"pmid":"18076668","id":"PMC_18076668","title":"Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation.","date":"2007","source":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18076668","citation_count":37,"is_preprint":false},{"pmid":"16215763","id":"PMC_16215763","title":"The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment.","date":"2005","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/16215763","citation_count":37,"is_preprint":false},{"pmid":"29477378","id":"PMC_29477378","title":"ICAM3 mediates inflammatory signaling to promote cancer cell stemness.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29477378","citation_count":36,"is_preprint":false},{"pmid":"23775590","id":"PMC_23775590","title":"Novel role of ICAM3 and LFA-1 in the clearance of apoptotic neutrophils by human macrophages.","date":"2013","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/23775590","citation_count":36,"is_preprint":false},{"pmid":"7876557","id":"PMC_7876557","title":"CD50 (ICAM-3) is phosphorylated on tyrosine and is associated with tyrosine kinase activity in human neutrophils.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7876557","citation_count":35,"is_preprint":false},{"pmid":"18073208","id":"PMC_18073208","title":"Structural requirements for multimerization of the pathogen receptor dendritic cell-specific ICAM3-grabbing non-integrin (CD209) on the cell surface.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18073208","citation_count":34,"is_preprint":false},{"pmid":"15880373","id":"PMC_15880373","title":"Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15880373","citation_count":32,"is_preprint":false},{"pmid":"22479382","id":"PMC_22479382","title":"RUNX3 regulates intercellular adhesion molecule 3 (ICAM-3) expression during macrophage differentiation and monocyte extravasation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22479382","citation_count":31,"is_preprint":false},{"pmid":"8132828","id":"PMC_8132828","title":"Cellular distribution of human leucocyte adhesion molecule ICAM-3.","date":"1994","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8132828","citation_count":31,"is_preprint":false},{"pmid":"11739669","id":"PMC_11739669","title":"Binding of LFA-1 (CD11a) to intercellular adhesion molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) triggers transmigration of human immunodeficiency virus type 1-infected monocytes through mucosal epithelial cells.","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11739669","citation_count":30,"is_preprint":false},{"pmid":"7531103","id":"PMC_7531103","title":"LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids.","date":"1994","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/7531103","citation_count":30,"is_preprint":false},{"pmid":"8214000","id":"PMC_8214000","title":"ICAM-3 expression on endothelium in lymphoid malignancy.","date":"1993","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8214000","citation_count":30,"is_preprint":false},{"pmid":"7875209","id":"PMC_7875209","title":"Epitope mapping and functional properties of anti-intercellular adhesion molecule-3 (CD50) monoclonal antibodies.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7875209","citation_count":29,"is_preprint":false},{"pmid":"7876564","id":"PMC_7876564","title":"Existence of a soluble form of CD50 (intercellular adhesion molecule-3) produced upon human lymphocyte activation. Present in normal human serum and levels are increased in the serum of systemic lupus erythematosus patients.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7876564","citation_count":29,"is_preprint":false},{"pmid":"19029201","id":"PMC_19029201","title":"Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages.","date":"2008","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19029201","citation_count":29,"is_preprint":false},{"pmid":"17570115","id":"PMC_17570115","title":"Association of ICAM3 genetic variant with severe acute respiratory syndrome.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17570115","citation_count":28,"is_preprint":false},{"pmid":"17145745","id":"PMC_17145745","title":"DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes through Lewis x residues.","date":"2006","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17145745","citation_count":28,"is_preprint":false},{"pmid":"7737271","id":"PMC_7737271","title":"Heterogenous glycosylation of ICAM-3 and lack of interaction with Mac-1 and p150,95.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7737271","citation_count":27,"is_preprint":false},{"pmid":"27552332","id":"PMC_27552332","title":"Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease.","date":"2017","source":"Journal of clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27552332","citation_count":26,"is_preprint":false},{"pmid":"9605163","id":"PMC_9605163","title":"Coengagement of ICAM-3 and Fc receptors induces chemokine secretion and spreading by myeloid leukocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9605163","citation_count":24,"is_preprint":false},{"pmid":"9766501","id":"PMC_9766501","title":"Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9766501","citation_count":23,"is_preprint":false},{"pmid":"10189240","id":"PMC_10189240","title":"ICAM-3 and E-selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas.","date":"1999","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10189240","citation_count":23,"is_preprint":false},{"pmid":"11179968","id":"PMC_11179968","title":"Structural study of N-linked oligosaccharides of human intercellular adhesion molecule-3 (CD50).","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11179968","citation_count":22,"is_preprint":false},{"pmid":"29729315","id":"PMC_29729315","title":"ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29729315","citation_count":21,"is_preprint":false},{"pmid":"18678668","id":"PMC_18678668","title":"Binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50.","date":"2008","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18678668","citation_count":21,"is_preprint":false},{"pmid":"9131010","id":"PMC_9131010","title":"Antibodies to the beta 1-integrin chain, CD44, or ICAM-3 stimulate adhesion of blast colony-forming cells and may inhibit their growth.","date":"1997","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9131010","citation_count":21,"is_preprint":false},{"pmid":"29662482","id":"PMC_29662482","title":"Targeting Mycobacterium tuberculosis Antigens to Dendritic Cells via the DC-Specific-ICAM3-Grabbing-Nonintegrin Receptor Induces Strong T-Helper 1 Immune Responses.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29662482","citation_count":19,"is_preprint":false},{"pmid":"7544645","id":"PMC_7544645","title":"B-cell homotypic adhesion through exon-A restricted epitopes of CD45 involves LFA-1/ICAM-1, ICAM-3 interactions, and induces coclustering of CD45 and LFA-1.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7544645","citation_count":19,"is_preprint":false},{"pmid":"10891379","id":"PMC_10891379","title":"Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10891379","citation_count":19,"is_preprint":false},{"pmid":"7851905","id":"PMC_7851905","title":"The human intercellular adhesion molecule 3 (ICAM3) gene is located in the 19p13.2-p13.3 region, close to the ICAM1 gene.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7851905","citation_count":18,"is_preprint":false},{"pmid":"14726630","id":"PMC_14726630","title":"ICAM-3 activation modulates cell-cell contacts of human bone marrow endothelial cells.","date":"2004","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/14726630","citation_count":18,"is_preprint":false},{"pmid":"10688433","id":"PMC_10688433","title":"Regulation of ICAM-3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone.","date":"1999","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/10688433","citation_count":17,"is_preprint":false},{"pmid":"7539471","id":"PMC_7539471","title":"Intercellular adhesion molecule-3 (CD50) on human epidermal Langerhans cells participates in T-cell activation.","date":"1995","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7539471","citation_count":15,"is_preprint":false},{"pmid":"9834117","id":"PMC_9834117","title":"Engagement of ICAM-3 activates polymorphonuclear leukocytes: aggregation without degranulation or beta 2 integrin recruitment.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9834117","citation_count":15,"is_preprint":false},{"pmid":"11261782","id":"PMC_11261782","title":"Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion--evidence for retinoid signaling pathways in the mast cell lineage.","date":"2001","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/11261782","citation_count":15,"is_preprint":false},{"pmid":"9008304","id":"PMC_9008304","title":"Stimulation through CD50 (ICAM-3) induces both activation and programmed cell death of human thymocytes.","date":"1996","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9008304","citation_count":14,"is_preprint":false},{"pmid":"7482494","id":"PMC_7482494","title":"CD50 (intercellular adhesion molecule-3) is expressed at higher levels on memory than on naive human T cells but induces a similar calcium mobilization on both subsets.","date":"1995","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/7482494","citation_count":14,"is_preprint":false},{"pmid":"9218600","id":"PMC_9218600","title":"CD50 monoclonal antibodies inhibit neutrophil activation.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9218600","citation_count":14,"is_preprint":false},{"pmid":"9828136","id":"PMC_9828136","title":"Mapping of the ICAM-5 (telencephalin) gene, a neuronal member of the ICAM family, to a location between ICAM-1 and ICAM-3 on human chromosome 19p13.2.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9828136","citation_count":14,"is_preprint":false},{"pmid":"10706734","id":"PMC_10706734","title":"CD4+ T cell and eosinophil adhesion is mediated by specific ICAM-3 ligation and results in eosinophil activation.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10706734","citation_count":14,"is_preprint":false},{"pmid":"1730238","id":"PMC_1730238","title":"Effect of protein kinase C activators on the phosphorylation and the surface expression of the CDw50 leukocyte antigen.","date":"1992","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1730238","citation_count":13,"is_preprint":false},{"pmid":"9686599","id":"PMC_9686599","title":"The leukocyte function-associated antigen-1 (LFA-1)-binding site on ICAM-3 comprises residues on both faces of the first immunoglobulin domain.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9686599","citation_count":13,"is_preprint":false},{"pmid":"10685862","id":"PMC_10685862","title":"Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.","date":"2000","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/10685862","citation_count":13,"is_preprint":false},{"pmid":"21381019","id":"PMC_21381019","title":"The neuronal protein Kidins220/ARMS associates with ICAM-3 and other uropod components and regulates T-cell motility.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21381019","citation_count":13,"is_preprint":false},{"pmid":"24177012","id":"PMC_24177012","title":"ICAM-3 endows anticancer drug resistance against microtubule-damaging agents via activation of the ICAM-3-AKT/ERK-CREB-2 pathway and blockage of apoptosis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24177012","citation_count":13,"is_preprint":false},{"pmid":"11493756","id":"PMC_11493756","title":"CD50 and CD62L adhesion receptor expression on naive (CD45RA+) and memory (CD45RO+) T lymphocytes in the elderly.","date":"2000","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11493756","citation_count":12,"is_preprint":false},{"pmid":"11083511","id":"PMC_11083511","title":"CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis.","date":"2000","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/11083511","citation_count":11,"is_preprint":false},{"pmid":"8546991","id":"PMC_8546991","title":"Expression of ICAM-3/CD50 in normal and diseased skin.","date":"1995","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8546991","citation_count":10,"is_preprint":false},{"pmid":"10380912","id":"PMC_10380912","title":"ICAM-3 (CD50) cross-linking augments signaling in CD3-activated peripheral human T lymphocytes.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10380912","citation_count":10,"is_preprint":false},{"pmid":"8946680","id":"PMC_8946680","title":"Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors.","date":"1996","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/8946680","citation_count":9,"is_preprint":false},{"pmid":"8429685","id":"PMC_8429685","title":"Isolation and characterisation of a CDw50 negative Jurkat T-cell line variant (PPL.1).","date":"1993","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/8429685","citation_count":8,"is_preprint":false},{"pmid":"31083610","id":"PMC_31083610","title":"ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31083610","citation_count":8,"is_preprint":false},{"pmid":"7782098","id":"PMC_7782098","title":"Expression of ICAM-3 on human epidermal dendritic cells.","date":"1995","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/7782098","citation_count":8,"is_preprint":false},{"pmid":"9929740","id":"PMC_9929740","title":"Stimulation through CD50 preferentially induces apoptosis of TCR1+ human peripheral blood lymphocytes.","date":"1998","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/9929740","citation_count":7,"is_preprint":false},{"pmid":"10626904","id":"PMC_10626904","title":"ICAM-3 (CD50) is expressed by human mast cells: induction of homotypic mast cell aggregation via ICAM-3.","date":"1999","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/10626904","citation_count":7,"is_preprint":false},{"pmid":"17434553","id":"PMC_17434553","title":"ICAM-3 influences human immunodeficiency virus type 1 replication in CD4(+) T cells independent of DC-SIGN-mediated transmission.","date":"2007","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/17434553","citation_count":7,"is_preprint":false},{"pmid":"17962491","id":"PMC_17962491","title":"An intercellular adhesion molecule-3 (ICAM-3) -grabbing nonintegrin (DC-SIGN) efficiently blocks HIV viral budding.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17962491","citation_count":6,"is_preprint":false},{"pmid":"15890347","id":"PMC_15890347","title":"ICAM-3, a ligand for DC-SIGN, was duplicated from ICAM-1 in mammalian evolution, but was lost in the rodent genome.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15890347","citation_count":6,"is_preprint":false},{"pmid":"7576578","id":"PMC_7576578","title":"Expression of the intercellular adhesion molecule-3 (ICAM-3) in human renal tissue with relation to kidney transplants and various inflammatory diseases.","date":"1995","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/7576578","citation_count":6,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51817,"output_tokens":8343,"usd":0.140298},"stage2":{"model":"claude-opus-4-6","input_tokens":12110,"output_tokens":4060,"usd":0.243075},"total_usd":0.383373,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"ICAM-3 (ICAM-R/CDw50) was identified as a third ligand for LFA-1 (CD11a/CD18), consisting of five immunoglobulin superfamily domains, constitutively expressed on all leukocytes, binding LFA-1 through its two N-terminal domains.\",\n      \"method\": \"Expression cloning of cDNA, functional adhesion assays with LFA-1\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — two independent groups cloned and functionally characterized ICAM-3 in the same issue, with binding assays confirming LFA-1 interaction\",\n      \"pmids\": [\"1448173\", \"1448174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"ICAM-3 and CDw50 are the same glycoprotein (~120 kDa), confirmed by immunochemical, functional, and peptide sequencing studies.\",\n      \"method\": \"Immunoprecipitation, peptide sequencing, functional assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (biochemical, functional, sequencing) confirming identity\",\n      \"pmids\": [\"8325327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"ICAM-3 is located at cellular uropods of T lymphoblasts and regulates the LFA-1/ICAM-1 adhesion pathway; engagement of ICAM-3 with activating mAb induces T cell aggregation dependent on LFA-1/ICAM-1 and enhances LFA-1 avidity for ICAM-1.\",\n      \"method\": \"Immunofluorescence microscopy, mAb blocking experiments, T lymphoblast adhesion assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — localization tied to functional consequence with multiple blocking experiments\",\n      \"pmids\": [\"7901223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"ICAM-3 acts as a co-stimulatory molecule for both resting and activated T lymphocytes; soluble purified ICAM-3 co-immobilized with anti-CD3 stimulated T lymphocyte activation (CD25 and CD69 expression), and this effect was blocked by anti-CD18, implicating LFA-1 as the mediating beta2 integrin.\",\n      \"method\": \"Immunoaffinity purification of ICAM-3, T cell co-stimulation assays, mAb blocking\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — purified protein reconstitution combined with mAb blocking, demonstrating mechanistic co-stimulation via LFA-1\",\n      \"pmids\": [\"8223855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The LFA-1 binding site on ICAM-3 resides in immunoglobulin domain 1; purified ICAM-3 supports LFA-1-dependent adhesion in a temperature- and cation-dependent manner, and two ICAM-3 mAbs (CBR-IC3/1 and CBR-IC3/2) together are required to fully block LFA-1-dependent adhesion. ICAM-3 also provides a costimulatory proliferative signal to resting T lymphocytes.\",\n      \"method\": \"Adhesion assays with purified ICAM-3, mAb blocking, T cell proliferation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted adhesion with purified protein, multiple mAb characterizations, replicated findings on co-stimulation\",\n      \"pmids\": [\"7905020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 engagement induces tyrosine phosphorylation of proteins (125, 70, and 38 kDa), and this signaling is regulated by the CD45 tyrosine phosphatase; inhibitors of tyrosine kinase activity and certain anti-CD45 mAbs abolished ICAM-3-mediated cell aggregation.\",\n      \"method\": \"Western blot for phosphotyrosine, immunofluorescence, inhibitor studies, mAb blocking\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemical and cell-based) linking ICAM-3 engagement to tyrosine kinase/phosphatase signaling\",\n      \"pmids\": [\"7520448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The LFA-1 I domain contains the binding site for ICAM-3; two anti-LFA-1 mAbs (YTH81.5 and 122.2A5) with I domain epitopes selectively block adhesion to ICAM-3 but not ICAM-1, demonstrating that LFA-1 binds ICAM-1 and ICAM-3 in a selective manner using the I domain.\",\n      \"method\": \"T cell adhesion assays to immobilized ligands, mAb epitope mapping, COS cell transfection adhesion assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean adhesion assays with transfected cells and panel of blocking mAbs, epitope mapping to I domain\",\n      \"pmids\": [\"7518468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 engagement by activating mAb HP2/19 regulates T lymphocyte morphology, induces a heading uropod-like structure where ICAM-3 concentrates distally, and enhances integrin-mediated (LFA-1, VLA-4, VLA-5) T cell adhesion to endothelial cells and extracellular matrix ligands.\",\n      \"method\": \"Immunofluorescence microscopy, T cell adhesion assays to ICAM-1, VCAM-1, fibronectin fragments, mAb blocking\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by microscopy linked to functional adhesion phenotypes with multiple blocking controls\",\n      \"pmids\": [\"7525599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CDw50/ICAM-3 cross-linking on Jurkat T cells induces calcium mobilization dependent on extracellular Ca2+ uptake and tyrosine phosphorylation, and p56lck and p59fyn protein tyrosine kinases are physically associated with ICAM-3 (co-immunoprecipitation).\",\n      \"method\": \"Calcium flux assays, in vitro kinase assays, immunoprecipitation with specific antisera for p56lck and p59fyn\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct co-immunoprecipitation of kinases with ICAM-3 plus in vitro kinase activity assay\",\n      \"pmids\": [\"7515097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 surface expression on neutrophils is down-regulated by a proteolytic shedding mechanism upon activation (PMA or calcium ionophore), releasing soluble ICAM-3 into the medium; protease inhibitors abrogate this down-regulation. A soluble form of ICAM-3 is detectable in plasma of healthy humans.\",\n      \"method\": \"125I-anti-ICAM-3 internalization assay, immunoprecipitation of cell-free supernatants, radioimmunoassay of plasma, protease inhibitor treatment\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods (radiolabel, immunoprecipitation, RIA) demonstrating proteolytic shedding mechanism\",\n      \"pmids\": [\"7525295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 (CD50) signaling through CD50 increases beta1 and beta2 integrin avidity (not surface expression) to enhance T lymphocyte adhesion to TNF-stimulated endothelial cells and extracellular matrix proteins, demonstrated by combined blocking of both integrin families.\",\n      \"method\": \"T cell adhesion assays to endothelial cells and ECM, mAb blocking of integrin chains, flow cytometry for integrin surface expression\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean mechanistic dissection with reciprocal blocking experiments and functional consequence\",\n      \"pmids\": [\"7515813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 on neutrophils is phosphorylated predominantly on tyrosine residues, and protein tyrosine kinase activity (including hck and lyn src-family kinases) is associated with CD50 in immunoprecipitates from human neutrophils.\",\n      \"method\": \"Radiolabeling, immunoprecipitation, phosphoamino acid analysis, in vitro kinase assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay on immunoprecipitate with phosphoamino acid analysis\",\n      \"pmids\": [\"7876557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The LFA-1 binding site on ICAM-3 involves a conserved integrin-binding motif in domain 1 including residues E37/T38, and Q75 (conserved in ICAM-1 and ICAM-2) confers specificity; electron microscopy shows ICAM-3 is a straight rod of 15 nm consistent with head-to-tail Ig domain arrangement.\",\n      \"method\": \"Electron microscopy, site-directed mutagenesis of ICAM-3, LFA-1-dependent adhesion assays\",\n      \"journal\": \"Cell adhesion and communication\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with structural EM and functional adhesion assays\",\n      \"pmids\": [\"7531103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Alpha-d/CD18 (alphaDbeta2), a fourth beta2 integrin, binds ICAM-3 preferentially over ICAM-1, identifying ICAM-3 as a preferred ligand for this integrin.\",\n      \"method\": \"Transfection of alpha-d cDNA, adhesion assays comparing ICAM-1 vs. ICAM-3\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional adhesion assays with transfected cells definitively characterizing ligand selectivity\",\n      \"pmids\": [\"8777714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ICAM-3 interacts with Mac-1 (CD11b) or p150,95 (CD11c) neither from lymphoid cells nor from neutrophils; purified Mac-1 does not support adhesion of ICAM-3-expressing transfectants, establishing ICAM-3 as not a counter-receptor for Mac-1 or p150,95.\",\n      \"method\": \"CHO cell transfection adhesion assays with purified Mac-1, L cell transfectants\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted adhesion assays with purified proteins and transfectants\",\n      \"pmids\": [\"7737271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The LFA-1 binding site on ICAM-3 maps exclusively to domain 1; deletion of individual Ig domains and chimeras with CD21 showed domain 1 is necessary and sufficient, and point mutagenesis identified five contact residues (Asn23, Ser25, Glu37, Phe54, Gln75) predicted to cluster on the BED face and C/E/FG regions of domain 1.\",\n      \"method\": \"Domain deletion mutagenesis, ICAM-3/CD21 chimeras, point mutagenesis (45 mutants), LFA-1 adhesion assays, mAb epitope mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — extensive mutagenesis (45 point mutants) combined with domain chimeras and functional adhesion assays\",\n      \"pmids\": [\"8798624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The LFA-1 I domain acts as a transient, Mg2+-dependent binding module for ICAM-3 in hydrodynamic flow; GPI-anchored I domain cells roll on ICAM-3 bilayers, and the LFA-1-activating antibody MEM-83 (which stimulates ICAM-1 binding) blocks interaction with ICAM-3, demonstrating distinct modes of I domain interaction with ICAM-1 vs. ICAM-3.\",\n      \"method\": \"GPI-anchored I domain cell expression, flow chamber rolling assays on lipid bilayers with purified ICAM-1/ICAM-3\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted system with purified ligands and defined adhesion assay under controlled flow\",\n      \"pmids\": [\"9271587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The LFA-1 binding site on ICAM-3 domain 1 includes residues on both the ABED face and the GFC face, unlike ICAM-1 where only GFC face residues interact with LFA-1; mutagenesis of 18 positions identified 7 residues reducing or abolishing LFA-1 adhesion.\",\n      \"method\": \"Point mutagenesis of 18 residues in domain 1, LFA-1 adhesion assays, mAb blocking studies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional adhesion assays\",\n      \"pmids\": [\"9686599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Engagement of ICAM-3 by a mAb recognizing the alphaLbeta2-binding region activates PMN homotypic aggregation through outside-in signaling: activating tyrosine kinase and PKC, reorganizing the cytoskeleton, and activating constitutive surface beta2 integrins without inducing degranulation or beta2 integrin recruitment.\",\n      \"method\": \"mAb engagement (Fab and F(ab')2 fragments), aggregation assays, kinase activity measurements, cytoskeletal reorganization assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Fab fragment experiments exclude Fc-mediated effects; multiple kinase assays and functional readouts\",\n      \"pmids\": [\"9834117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Co-engagement of ICAM-3 (domain 1 epitopes) with Fc receptors (FcgammaRI or FcgammaRII) on monocytes is required for maximal chemokine secretion (MIP-1alpha, IL-8, MCP-1); ICAM-3 engagement also induces monocyte spreading via direct outside-in signaling (Fab/F(ab')2-dependent).\",\n      \"method\": \"Immobilized mAb engagement, Fab/F(ab')2 fragments, chemokine ELISA, microscopy for cell spreading\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Fab fragment controls confirm direct ICAM-3 outside-in signaling; multiple cytokine readouts\",\n      \"pmids\": [\"9605163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ICAM-3 on apoptotic leukocytes acts as a phagocytic recognition signal for macrophages; the first Ig-like domain of ICAM-3 mediates macrophage recognition, and its binding preference shifts from LFA-1 to macrophage CD14 during apoptosis, enabling phagocytosis.\",\n      \"method\": \"mAb blockade of macrophage-apoptotic cell interactions, ICAM-3 transfection into non-leukocytes, apoptosis triggered by multiple stimuli\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mAb blocking, transfection into non-leukocytes, and multiple apoptotic stimuli provide strong evidence for mechanism\",\n      \"pmids\": [\"10352301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DC-SIGN, a DC-specific C-type lectin, binds ICAM-3 expressed on resting T cells with high affinity to mediate transient DC-T cell adhesion; anti-DC-SIGN antibodies inhibit DC-induced proliferation of resting T cells, indicating DC-SIGN/ICAM-3 stabilizes the DC-T cell contact zone.\",\n      \"method\": \"Binding assays, mAb inhibition of DC-T cell interaction and T cell proliferation, expression analysis of DC-SIGN on DC in vitro and in vivo\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — identification of novel receptor with functional blocking experiments, replicated in multiple systems\",\n      \"pmids\": [\"10721994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"LFA-1 (alphaLbeta2) preferentially binds ICAM-3 as its primary ligand supporting neutrophil homotypic adhesion at higher shear rates (>300 s-1), whereas Mac-1 is the predominant integrin at lower shear rates (~100 s-1); the contributions of LFA-1 and Mac-1 to ICAM-3-dependent aggregation are regulated by shear magnitude and stimulus duration.\",\n      \"method\": \"Cone-plate viscometer shear experiments, mAb blocking with panel of anti-LFA-1, anti-Mac-1, and anti-ICAM-3 antibodies, flow cytometry for aggregate formation kinetics\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative adhesion efficiency model with systematic mAb blocking across shear range\",\n      \"pmids\": [\"10725740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ICAM-3 N-linked oligosaccharides are mainly of tri- and tetra-antennary complex-type (~60% containing poly N-acetyllactosamine chains with type 1 structure), with a small amount of high-mannose type; approximately 6 mol oligosaccharides per mol ICAM-3.\",\n      \"method\": \"Hydrazinolysis to release N-glycans, paper electrophoresis, lectin column chromatography, sequential exo/endo-glycosidase digestion, methylation analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic structural analysis using multiple biochemical methods\",\n      \"pmids\": [\"11179968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ICAM-3 is specifically clustered at the region of the T lymphocyte surface that initiates contact with APCs (pre-immunological synapse), as shown by time-lapse imaging; ICAM-3 promotes early intracellular signaling and cytoskeletal rearrangement before antigen recognition.\",\n      \"method\": \"Time-lapse live-cell imaging, mAb blocking, analysis of T cell-APC conjugate formation, signaling and cytoskeletal assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live-cell time-lapse imaging directly linking ICAM-3 clustering to functional consequence (early signaling and cytoskeletal rearrangement)\",\n      \"pmids\": [\"11812993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DC-SIGN binds ICAM-3 from granulocytes via Lewis x glycan residues on ICAM-3; fucosyltransferase IX (FUT IX) is the main enzyme mediating Lewis x synthesis on ICAM-3, with FUT IV contributing to a lesser extent. ICAM-3 from granulocytes but not other leukocytes binds DC-SIGN.\",\n      \"method\": \"Recombinant DC-SIGN binding assays, anti-Lewis x mAbs, MALDI-TOF mass spectrometry, cotransfection studies with multiple FUTs, DC-SIGN-expressing immature DC binding experiments\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry structural confirmation plus functional FUT cotransfection assays with multiple enzymes\",\n      \"pmids\": [\"17145745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ICAM-3 stimulates cancer cell migration and invasion via an ICAM-3/Akt/CREB/MMP pathway; ICAM-3 overexpression increases Akt phosphorylation, activates CREB, and upregulates MMP-2 and MMP-9 expression and activity, leading to enhanced migration/invasion independent of p53 and PTEN status.\",\n      \"method\": \"Stable ICAM-3-overexpressing transfectants, migration/invasion assays, Akt inhibitor treatment, siRNA knockdown of CREB, gelatin zymography for MMP activity\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with OE and inhibitor/knockdown, but single-lab study\",\n      \"pmids\": [\"19956847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Apoptotic cell-derived ICAM-3 promotes macrophage chemoattraction via ICAM-3-bearing microparticles released during apoptosis; ICAM-3 on apoptotic cells mediates domain 1-2-dependent tethering to macrophages. ICAM-3-deficient microparticles show profound defect in chemotaxis.\",\n      \"method\": \"Novel anti-ICAM-3 mAbs (blocking and non-blocking), ICAM-3-deficient apoptotic leukocytes, microparticle isolation, chemotaxis assays, phagocytosis assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including blocking mAbs and ICAM-3-deficient cells, two distinct functional readouts (chemotaxis and tethering)\",\n      \"pmids\": [\"22117198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The RUNX3 transcription factor negatively regulates ICAM-3 gene expression; ICAM-3 promoter activity depends on RUNX binding sites, and siRNA-mediated reduction of RUNX3 increases ICAM-3 mRNA; ICAM-3 levels decrease during monocyte-to-macrophage differentiation correlating with increased RUNX3.\",\n      \"method\": \"Promoter-reporter assays, chromatin immunoprecipitation (RUNX binding in vivo), siRNA knockdown of RUNX3, protein level analysis during macrophage differentiation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis, ChIP, and gene silencing providing convergent evidence for RUNX3 as a negative transcriptional regulator\",\n      \"pmids\": [\"22479382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ICAM-3 and LFA-1 act as recognition receptors in phagocytosis portals of macrophages for engulfment of apoptotic neutrophils; ICAM-3 on macrophages is upregulated upon exposure to apoptotic neutrophils, blocking ICAM-3 on macrophages or apoptotic neutrophils reduces phagocytosis, and ICAM-3/LFA-1 co-localize in phagocytic portals.\",\n      \"method\": \"Gene silencing (siRNA), blocking antibodies, fluorescence microscopy, phagocytosis quantification\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal siRNA and blocking experiments on both cell types with co-localization evidence in phagocytic portals\",\n      \"pmids\": [\"23775590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ICAM-3 recruits and binds Src kinase through the YLPL motif in its intracellular domain, activating PI3K-AKT phosphorylation cascades that enhance SOX2 and OCT4 activity to maintain cancer cell stemness; p-AKT also facilitates p50 nuclear translocation which feeds back to enhance ICAM-3 expression by binding its promoter.\",\n      \"method\": \"siRNA screen, co-immunoprecipitation of ICAM-3 with Src, PI3K/Src inhibitor treatment, in vivo tumor and metastasis models with shICAM-3 cells\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus pharmacological inhibition plus in vivo models, but single-lab study\",\n      \"pmids\": [\"29477378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ICAM-3 mediates tumor metastasis via a LFA-1-ICAM-3-ERM-dependent mechanism; ICAM-3 binds LFA-1 through its extracellular domain and ERM scaffold proteins and lamellipodia through its intracellular domain, creating tension that facilitates cell motility; extracellular or intracellular mutants of ICAM-3 abolish metastasis, and LFA-1 antibody or Lifitegrast inhibit ICAM-3-LFA-1-mediated metastasis.\",\n      \"method\": \"ICAM-3 extracellular/intracellular domain mutants, co-immunoprecipitation with ERM proteins, in vitro and in vivo metastasis assays, LFA-1 antibody treatment\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutants plus co-IP plus in vivo models, single lab\",\n      \"pmids\": [\"29729315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"ICAM-3 (CDw50) is constitutively non-phosphorylated at baseline but becomes rapidly phosphorylated on serine residues within 1–5 minutes upon stimulation with protein kinase C activators (PMA, PDB, mezerein), and PKC inhibitors (staurosporine, H-7) reduce this phosphorylation, implicating PKC-mediated mechanisms in ICAM-3 phosphorylation.\",\n      \"method\": \"Radiolabeling (32P), immunoprecipitation, phosphoamino acid analysis, PKC inhibitor treatment\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical phosphorylation analysis with phosphoamino acid identification and pharmacological inhibition\",\n      \"pmids\": [\"1730238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Activation of ICAM-3 on human bone marrow endothelial cells by crosslinking with specific antibodies causes loss of endothelial cell-cell contacts and drop in electrical resistance; biochemical analysis reveals ICAM-3 associates with moesin (and later ezrin) upon crosslinking, and induces production of reactive oxygen species (ROS) that mediate endothelial permeability.\",\n      \"method\": \"ICAM-3 crosslinking, electrical resistance measurement of endothelial monolayers, immunocytochemistry, co-immunoprecipitation of moesin/ezrin with ICAM-3, ROS measurement\",\n      \"journal\": \"Journal of vascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus functional monolayer integrity assay with ROS detection, but single lab\",\n      \"pmids\": [\"14726630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Kidins220/ARMS protein co-immunoprecipitates with ICAM-3 and co-localizes at the uropod of polarized T lymphocytes; disruption of cell polarity (PKC-dependent) impairs Kidins220/ARMS association with ICAM-3; Kidins220/ARMS knockdown promotes T cell migration, identifying it as a uropod regulator linked to ICAM-3.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence microscopy in polarized T cells, siRNA knockdown, directed migration assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single co-IP with partial mechanistic follow-up (PKC dependence and migration assays)\",\n      \"pmids\": [\"21381019\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ICAM-3 (CD50) is an immunoglobulin superfamily cell adhesion molecule constitutively expressed on all leukocytes that functions as the primary LFA-1 (CD11a/CD18) ligand on resting T cells—binding through residues on both faces of its first Ig domain—and also serves as a ligand for alphaDbeta2 and DC-SIGN; it concentrates at the T cell uropod and the initial DC-contact zone to promote antigen-independent adhesion and provide LFA-1-mediated co-stimulation through outside-in signaling (activating p56lck, p59fyn, tyrosine phosphorylation, and Ca2+ flux, regulated by CD45 phosphatase), is shed proteolytically from activated neutrophils as a soluble form, acts as an altered-recognition eat-me signal on apoptotic leukocytes engaging macrophage CD14, and drives cancer cell migration/stemness through intracellular YLPL-Src-PI3K-AKT and ERM-lamellipodia interactions.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ICAM-3 (CD50) is an immunoglobulin superfamily adhesion molecule constitutively expressed on leukocytes that functions as a principal ligand for LFA-1 (αLβ2) and αDβ2 integrins, and for the C-type lectin DC-SIGN, thereby orchestrating leukocyte adhesion, T cell co-stimulation, dendritic cell–T cell contact, and apoptotic cell clearance. LFA-1 binds ICAM-3 through its I domain at residues distributed across both the ABED and GFC faces of Ig domain 1, a binding mode distinct from that used for ICAM-1; this interaction mediates outside-in signaling that activates Src-family kinases (p56lck, p59fyn, hck, lyn), PKC, and tyrosine phosphorylation cascades regulated by the CD45 phosphatase, resulting in calcium mobilization, cytoskeletal reorganization, integrin avidity upregulation, and T cell co-stimulation [PMID:1448173, PMID:7905020, PMID:7515097, PMID:7520448, PMID:9686599]. ICAM-3 concentrates at the T cell uropod and the initial T cell–APC contact zone to promote early antigen-independent adhesion and signaling prior to immunological synapse formation, and DC-SIGN on dendritic cells engages Lewis x glycans on ICAM-3 to stabilize this contact [PMID:7525599, PMID:11812993, PMID:10721994, PMID:17145745]. On apoptotic leukocytes, ICAM-3 undergoes an altered-recognition switch from LFA-1 to macrophage CD14, functioning as an eat-me signal that promotes phagocytosis and releases ICAM-3-bearing microparticles that attract macrophages; additionally, in cancer cells, intracellular ICAM-3 recruits Src via its YLPL motif and signals through PI3K–AKT to drive migration, invasion, and stemness maintenance [PMID:10352301, PMID:22117198, PMID:29477378, PMID:29729315].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification of ICAM-3 as a third LFA-1 ligand on leukocytes established a new adhesion molecule in the immunoglobulin superfamily with distinct expression and potential function from ICAM-1 and ICAM-2.\",\n      \"evidence\": \"Two independent groups expression-cloned ICAM-3 cDNA and demonstrated LFA-1-dependent adhesion in functional assays\",\n      \"pmids\": [\"1448173\", \"1448174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding-site residues on ICAM-3 not yet mapped\", \"Signaling consequences of engagement unknown\", \"Relationship to CDw50 antigen not formally proven\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstration that ICAM-3 cytoplasmic domain undergoes rapid PKC-dependent serine phosphorylation revealed that ICAM-3 is a regulated signaling-competent molecule, not merely a passive adhesion scaffold.\",\n      \"evidence\": \"32P-radiolabeling and phosphoamino acid analysis of immunoprecipitated ICAM-3 with PKC activators and inhibitors\",\n      \"pmids\": [\"1730238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific serine residues not identified\", \"Functional consequence of phosphorylation not determined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Localization of ICAM-3 to the T cell uropod and demonstration that its engagement enhances LFA-1 avidity for ICAM-1 established ICAM-3 as an active regulator of integrin-mediated adhesion rather than simply a redundant LFA-1 counter-receptor.\",\n      \"evidence\": \"Immunofluorescence microscopy of T lymphoblasts combined with mAb blocking experiments and adhesion assays\",\n      \"pmids\": [\"7901223\", \"8223855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking ICAM-3 engagement to integrin activation not defined\", \"Whether co-stimulatory function requires uropod localization unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"A wave of signaling studies revealed that ICAM-3 engagement triggers tyrosine phosphorylation, calcium flux, and association with Src-family kinases (p56lck, p59fyn in T cells; hck, lyn in neutrophils), with CD45 phosphatase serving as a negative regulator — defining ICAM-3 as a bona fide outside-in signaling receptor.\",\n      \"evidence\": \"Co-immunoprecipitation of kinases with ICAM-3, in vitro kinase assays, phosphotyrosine blotting, calcium flux measurements, and CD45 mAb/inhibitor blocking in T cells and neutrophils\",\n      \"pmids\": [\"7520448\", \"7515097\", \"7876557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation substrates downstream of Src kinases not identified\", \"Whether kinase association is direct or scaffolded unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapping the LFA-1 binding site to Ig domain 1 of ICAM-3 and defining key contact residues (E37, T38, Q75) by mutagenesis and electron microscopy provided the first structural framework for ICAM-3–LFA-1 interaction.\",\n      \"evidence\": \"Site-directed mutagenesis of domain 1, LFA-1 adhesion assays, domain deletion/chimera analysis, electron microscopy showing 15 nm rod\",\n      \"pmids\": [\"7531103\", \"7905020\", \"8798624\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of ICAM-3 domain 1 or ICAM-3–I domain complex\", \"Role of glycosylation in LFA-1 binding not addressed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Discovery of proteolytic shedding of ICAM-3 from activated neutrophils and detection of soluble ICAM-3 in plasma identified a regulatory mechanism for surface ICAM-3 levels with potential immunomodulatory function.\",\n      \"evidence\": \"125I-radiolabel internalization assay, immunoprecipitation of supernatants, radioimmunoassay of plasma, protease inhibitor treatment\",\n      \"pmids\": [\"7525295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the protease(s) responsible for shedding not determined\", \"Functional role of soluble ICAM-3 in vivo unclear\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of αDβ2 as a second integrin receptor preferring ICAM-3 over ICAM-1 expanded the functional repertoire of ICAM-3 beyond LFA-1, while Mac-1 and p150,95 were excluded as ICAM-3 receptors.\",\n      \"evidence\": \"Transfection of αD cDNA with adhesion assays comparing ICAM-1 vs ICAM-3; purified Mac-1 adhesion assays with ICAM-3 transfectants\",\n      \"pmids\": [\"8777714\", \"7737271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context for αDβ2–ICAM-3 interaction not defined\", \"Whether αDβ2 and LFA-1 compete for the same ICAM-3 binding site unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Refined mutagenesis revealed that LFA-1 contacts both the ABED and GFC faces of ICAM-3 domain 1, unlike ICAM-1 where only the GFC face is used, establishing a structurally distinct binding mode that explains selective antibody blocking patterns.\",\n      \"evidence\": \"Systematic point mutagenesis of 18 residues in domain 1 combined with LFA-1 adhesion assays and mAb mapping\",\n      \"pmids\": [\"9686599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure to confirm dual-face binding model\", \"Conformational dynamics of the interaction not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The discovery that ICAM-3 on apoptotic leukocytes shifts from an LFA-1 ligand to a macrophage CD14 ligand established ICAM-3 as a phagocytic recognition ('eat-me') signal, revealing a non-adhesion function for this molecule.\",\n      \"evidence\": \"mAb blockade of macrophage–apoptotic cell interactions, ICAM-3 transfection into non-leukocyte cells, multiple apoptotic stimuli\",\n      \"pmids\": [\"10352301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the molecular change on ICAM-3 during apoptosis not defined\", \"Whether glycan modification mediates the ligand switch unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of DC-SIGN as a high-affinity ICAM-3 receptor on dendritic cells established a new axis for antigen-independent DC–T cell contact that initiates the immunological synapse.\",\n      \"evidence\": \"Binding assays and mAb inhibition of DC-SIGN–ICAM-3 interaction blocking DC-induced T cell proliferation\",\n      \"pmids\": [\"10721994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of DC-SIGN vs LFA-1 to DC–T cell adhesion not quantified\", \"Downstream signaling in DC upon DC-SIGN–ICAM-3 engagement not characterized\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Live-cell imaging demonstrated that ICAM-3 clusters at the initial T cell–APC contact zone before antigen recognition, positioning it as a key molecule in pre-immunological synapse formation and early signaling.\",\n      \"evidence\": \"Time-lapse live-cell imaging of T cell–APC conjugate formation with mAb blocking and cytoskeletal analysis\",\n      \"pmids\": [\"11812993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism driving ICAM-3 clustering to the contact zone not identified\", \"Whether ICAM-3 clustering requires DC-SIGN engagement or LFA-1 engagement unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that DC-SIGN recognizes Lewis x glycan structures on ICAM-3 (synthesized by FUT IX) resolved the glycan basis of the DC-SIGN–ICAM-3 interaction and explained cell-type-specific binding (granulocyte ICAM-3 binds DC-SIGN, other leukocyte ICAM-3 does not).\",\n      \"evidence\": \"MALDI-TOF mass spectrometry of ICAM-3 glycans, FUT cotransfection experiments, anti-Lewis x mAb blocking, DC-SIGN binding assays\",\n      \"pmids\": [\"17145745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Lewis x on T cell ICAM-3 is regulated during activation unknown\", \"Structural basis of DC-SIGN selectivity for Lewis x on ICAM-3 vs other glycoproteins not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstration that apoptotic cells release ICAM-3-bearing microparticles that serve as macrophage chemoattractants extended the eat-me signal concept to a 'find-me' signal, showing ICAM-3 domains 1–2 mediate both tethering and chemotaxis.\",\n      \"evidence\": \"ICAM-3-deficient apoptotic leukocytes, microparticle isolation, chemotaxis and phagocytosis assays with blocking and non-blocking mAbs\",\n      \"pmids\": [\"22117198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor on macrophages mediating ICAM-3-microparticle chemotaxis not definitively identified\", \"Whether soluble shed ICAM-3 and microparticle-bound ICAM-3 have overlapping or distinct functions unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"In cancer cells, ICAM-3 was shown to recruit Src kinase via the intracellular YLPL motif and activate PI3K–AKT signaling to maintain stemness (SOX2/OCT4) and drive metastasis through ERM-scaffold-dependent lamellipodia formation, extending ICAM-3 function beyond immune adhesion.\",\n      \"evidence\": \"Co-immunoprecipitation of ICAM-3 with Src and ERM proteins, PI3K/Src inhibitor treatment, intracellular/extracellular domain mutants, in vivo tumor and metastasis models\",\n      \"pmids\": [\"29477378\", \"29729315\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cancer-related findings from single laboratories, not independently confirmed\", \"Whether YLPL-Src and ERM interactions occur simultaneously or are context-dependent unknown\", \"Relevance of these mechanisms to normal leukocyte biology not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No atomic-resolution structure of ICAM-3 (alone or in complex with LFA-1, DC-SIGN, or CD14) exists, and the molecular basis of the apoptotic ligand switch from LFA-1 to CD14 remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of ICAM-3 or its complexes\", \"Mechanism of ICAM-3 modification during apoptosis unknown\", \"Identity of the sheddase(s) cleaving ICAM-3 from neutrophils not determined\", \"In vivo phenotype of ICAM-3 deficiency in humans or knockout animals not reported\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 3, 4, 7, 10, 21, 22]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [5, 8, 18, 19]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [13, 20, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 7, 9, 24]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [9, 27]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 5, 8, 21, 24, 29]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [2, 7, 10, 22, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 8, 18, 26, 30]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [20, 27, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ITGAL\",\n      \"ITGB2\",\n      \"CD209\",\n      \"CD14\",\n      \"LCK\",\n      \"FYN\",\n      \"MSN\",\n      \"EZR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}